title: Immunohistochemical staining for TLE1 distinguishes synovial sarcoma from histologic mimics.
abstract: Transducer-like enhancer of split 1 (TLE1) is overexpressed in synovial sarcomas. We investigated TLE1 expression by immunohistochemical analysis in a well-characterized series of synovial sarcomas and other mesenchymal tumors most commonly considered in the differential diagnosis. Whole tissue sections of 212 tumors were evaluated: 73 synovial sarcomas (23 biphasic, 28 monophasic, 22 poorly differentiated), 47 malignant peripheral nerve sheath tumors (MPNSTs), 49 solitary fibrous tumors (SFTs), 20 fibrosarcomatous variants of dermatofibrosarcoma protuberans, and 23 Ewing sarcomas/primitive neuroectodermal tumors (PNETs). All monophasic and poorly differentiated SSs and Ewing sarcoma/PNETs were previously confirmed to harbor t(X;18) and EWSR1 gene rearrangements, respectively. In total, 60 (82%) of 73 synovial sarcomas were positive for TLE1, including 18 biphasic (78%), 22 monophasic (79%), and 20 poorly differentiated (91%) tumors. Of the other tumors, only 7 MPNSTs (15%) and 4 SFTs (8%) were positive for TLE1, most of which showed only weak staining. TLE1 is a sensitive and specific marker for synovial sarcoma and can be helpful to distinguish synovial sarcoma from histologic mimics, particularly if moderate or strong staining is observed. In this study, only a small subset of MPNSTs and SFTs showed limited staining for TLE1.
authors.affiliation: Dept. of Pathology, Brigham and Women's Hospital, 75 Francis St., Boston, MA 02115, USA.
authors.forename: Wai Chin
authors.initials: WC
authors.lastname: Foo
authors.forename: Michael W
authors.initials: MW
authors.lastname: Cruise
authors.forename: Mark R
authors.initials: MR
authors.lastname: Wick
authors.forename: Jason L
authors.initials: JL
authors.lastname: Hornick
mesh_terms: D001859:Bone Neoplasms / Q000378:metabolism / Q000473:pathology; D056970:Co-Repressor Proteins; D018223:Dermatofibrosarcoma / Q000378:metabolism / Q000473:pathology; D003937:Diagnosis, Differential; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods*; D018317:Nerve Sheath Neoplasms / Q000378:metabolism / Q000473:pathology; D018242:Neuroectodermal Tumors, Primitive / Q000378:metabolism / Q000473:pathology; D012097:Repressor Proteins / Q000378:metabolism*; D012512:Sarcoma, Ewing / Q000378:metabolism / Q000473:pathology; D013584:Sarcoma, Synovial / Q000378:metabolism* / Q000473:pathology*; D012680:Sensitivity and Specificity; D012878:Skin Neoplasms / Q000378:metabolism / Q000473:pathology; D054364:Solitary Fibrous Tumors / Q000378:metabolism / Q000473:pathology; D013194:Staining and Labeling
chemical_list: D056970:Co-Repressor Proteins; D012097:Repressor Proteins; C499043:TLE1 protein, human